Guo Y, Raventós B, Català M, Elhussein L, López-Güell K, Tan EH, Prats-Uribe A, Dedman D, Man WY, Omulo H, Delmestri A, Lane JCE, Rahman U, Griffin XL, Gao C, Cole C, Batty P, Connelly J, Booth H, Cave A, Donegan K, Prieto-Alhambra D, Burn E and Jödicke AM Aten Primaria.2022 Aug; 54(9):102437.doi:10.1002/pds.70022 PMID:39414581
PURPOSE: To illustrate the interest in using interrupted time series (ITS) methods, this study evaluated the impact of the UK MHRA’s March 2019 Risk Minimisation Measures (RMM) on fluoroquinolone usage. METHODS: Monthly and quarterly fluoroquinolone use incidence rates from 2012 to 2022 were analysed across hospital care (Barts Health NHS Trust), primary care (Clinical Practice Research Datalink (CPRD) Aurum and CPRD GOLD), and linked records from both settings (East Scotland). Rates were stratified by age (19-59 and = 60 years old). Seasonality-adjusted segmented regression and ARIMA models were employed to model quarterly and monthly rates, respectively. RESULTS: Post-RMM, with segmented regression, both age groups in Barts Health experienced nearly complete reductions (> 99%); CPRD Aurum saw 20.19% (19-59) and 19.29% ( = 60) reductions; no significant changes in CPRD GOLD; East Scotland had 45.43% (19-59) and 41.47% ( = 60) decreases. Slope analysis indicated increases for East Scotland (19-59) and both CPRD Aurum groups, but a decrease for CPRD GOLD’s = 60; ARIMA detected significant step changes in CPRD GOLD not identified by segmented regression and noted a significant slope increase in Barts Health’s 19-59 group. Both models showed no post-modelling autocorrelations across databases, yet Barts Health’s residuals were non-normally distributed with non-constant variance. CONCLUSIONS: Both segmented regression and ARIMA confirmed the reduction of fluoroquinolones use after RMM across four different UK primary care and hospital databases. Model diagnostics showed good performance in eliminating residual autocorrelation for both methods. However, diagnostics for hospital databases with low incident use revealed the presence of heteroscedasticity and non-normal white noise using both methods.
G. CORBY, N. BARCLAY, E. TAN, E. BURN, A. DELMESTRI, T. DUARTE-SALLES, A. GOLOZAR, W. MAN, I. TIETZOVA, D. PRIETO-ALHAMBRA and D. NEWBY Aten Primaria.2022 Aug; 54(9):102437.doi:10.21037/tlcr-24-241 PMID:39430337
Background: Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases.Methods: We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method. Results: Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males. Conclusions: The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen
Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A, Serrano ÀR, Duarte-Salles T, Cornford P, Prieto Alhambra D and Newby D Aten Primaria.2022 Aug; 54(9):102437.doi:10.1001/jamanetworkopen.2024.34622 PMID:39298169
IMPORTANCE: Incidence, prevalence, and survival are pertinent measures to inform the management and provision of prostate cancer care. OBJECTIVE: To calculate the incidence, prevalence, and survival rates for prostate cancer in the UK from 2000 to 2021. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study uses routinely collected primary care data from the UK. Male patients aged 18 years or older with at least 1 year of history registered in Clinical Practice Research Datalink (CPRD) GOLD or Aurum were included. Data were analyzed from January 2023 to March 2024. MAIN OUTCOMES AND MEASURES: Prostate cancer incidence rates (IR), period prevalence (PP), and 1-, 5-, and 10-year survival after diagnosis between 2000 and 2021, stratified by age and calendar years. RESULTS: This study included 64?925 and 133?200 patients with prostate cancer in CPRD GOLD and Aurum, respectively, with a median age of 72 (65-78) years. The overall IR of prostate cancer was 151.7 (95% CI, 150.6 to 152.9) per 100?000 person-years in GOLD to 153.1 (95% CI, 152.3 to 153.9) per 100?000 person-years for Aurum and increased with age. The incidence of prostate cancer increased from 109 per 100 000 person-years in 2000 to 159 per 100 000 person-years in 2021. Peaks of incidence occurred in 2004 and 2018, before a decline in 2020. PP increased 3.5 times over the study period for both databases, from 0.4% in 2000 to 1.4% in 2021. IR and PP were highest in those aged 80 to 89 years. Median (95% CI) survival was similar in both databases (GOLD: 10.9 [95% CI, 10.7-11.1] years and Aurum: 11.1 [95% CI, 11.0-11.2] years). Survival at 1, 5, and 10 years after diagnosis were 93.4% (95% CI, 93.2%-93.6%), 71.8% (95% CI, 71.4%-72.2%), 53.2% (95% CI, 52.6%-53.7%) in GOLD and 93.9% (95% CI, 93.7%-94.0%), 72.7% (95% CI, 72.5%-73.0%), 53.7% (95% CI, 53.3%-54.1%) in AURUM, respectively. Survival increased over time: 1-year survival was 94.8% (95% CI, 94.5%-95.2%) in those diagnosed between 2015 to 2019 compared with 90.8% (95% CI, 90.2%-91.3%) from 2000 to 2004; 5-year survival improved from 65.3% (95% CI, 64.4%-66.3%) from 2000 to 2004 to 75.3% (95% CI, 74.4%-76.3%) in 2015 to 2019. CONCLUSIONS AND RELEVANCE: In this population-based cohort study, incidence and prevalence increased with older age, with high survival rates reflecting a high burden of disease, particularly in the management of cancer survivorship in an aging population. Health care systems should consider this when managing the increasing numbers of people with prevalent prostate cancer.
Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand TV, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Kaur G, Lau WCY, Li J, Li K, Liu Y, Lu Y, Man KKC, Matheny ME, Mathioudakis N, McLeggon JA, McLemore MF, Minty E, Morales DR, Nagy P, Ostropolets A, Pistillo A, Phan TP, Pratt N, Reyes C, Richter L, Ross JS, Ruan E, Seager SL, Simon KR, Viernes B, Yang J, Yin C, You SC, Zhou JJ, Ryan PB, Schuemie MJ, Krumholz HM, Hripcsak G and Suchard MA Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.jacc.2024.05.069 PMID:39197980
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head clinical trials. OBJECTIVES: The aim of this study was to compare the cardiovascular effectiveness of SGLT2is, GLP-1 RAs, dipeptidyl peptidase-4 inhibitors (DPP4is), and clinical sulfonylureas (SUs) as second-line antihyperglycemic agents in T2DM. METHODS: Across the LEGEND-T2DM (Large-Scale Evidence Generation and Evaluation Across a Network of Databases for Type 2 Diabetes Mellitus) network, 10 federated international data sources were included, spanning 1992 to 2021. In total, 1,492,855 patients with T2DM and cardiovascular disease (CVD) on metformin monotherapy were identified who initiated 1 of 4 second-line agents (SGLT2is, GLP-1 RAs, DPP4is, or SUs). Large-scale propensity score models were used to conduct an active-comparator target trial emulation for pairwise comparisons. After evaluating empirical equipoise and population generalizability, on-treatment Cox proportional hazards models were fit for 3-point MACE (myocardial infarction, stroke, and death) and 4-point MACE (3-point MACE plus heart failure hospitalization) risk and HR estimates were combined using random-effects meta-analysis. RESULTS: Over 5.2 million patient-years of follow-up and 489 million patient-days of time at risk, patients experienced 25,982 3-point MACE and 41,447 4-point MACE. SGLT2is and GLP-1 RAs were associated with lower 3-point MACE risk than DPP4is (HR: 0.89 [95% CI: 0.79-1.00] and 0.83 [95% CI: 0.70-0.98]) and SUs (HR: 0.76 [95% CI: 0.65-0.89] and 0.72 [95% CI: 0.58-0.88]). DPP4is were associated with lower 3-point MACE risk than SUs (HR: 0.87; 95% CI: 0.79-0.95). The pattern for 3-point MACE was also observed for the 4-point MACE outcome. There were no significant differences between SGLT2is and GLP-1 RAs for 3-point or 4-point MACE (HR: 1.06 [95% CI: 0.96-1.17] and 1.05 [95% CI: 0.97-1.13]). CONCLUSIONS: In patients with T2DM and CVD, comparable cardiovascular risk reduction was found with SGLT2is and GLP-1 RAs, with both agents more effective than DPP4is, which in turn were more effective than SUs. These findings suggest that the use of SGLT2is and GLP-1 RAs should be prioritized as second-line agents in those with established CVD.
M. DE RIDDER, J. ARINZE, G. INBERG, A. DELMESTRI, E. BURN, M. MAYER, A. LEIS, J. RAMIREZ, R. KOLDE, M. OJA, N. BESORA, T. SALLES and K. MC VERHAMME Aten Primaria.2022 Aug; 54(9):102437.doi:10.1183/13993003.congress-2024.OA4579 PMID:
J. ARINZE, M. MAYER, G. VERDY, M. VAN KESSEL, J. RAMÍREZ-ANGUITA, A. LEIS, M. OJA, R. KOLDE, A. DELMESTRI, H. OMULO, L. PÉREZ-CRESPO, J. BRASH, D. VOJINOVIC, H. BALLEGOOIJEN, S. SEAGER, T. DUARTE-SALLES and K. VERHAMME Aten Primaria.2022 Aug; 54(9):102437.doi:10.1183/13993003.congress-2024.PA3294 PMID:
Tonne C, Ranzani O, Alari A, Ballester J, Basagaña X, Chaccour C, Dadvand P, Duarte T, Foraster M, Milà C, Nieuwenhuijsen MJ, Olmos S, Rico A, Sunyer J, Valentín A and Vivanco R Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:39468856
INTRODUCTION: Evidence from epidemiological studies based on individual-level data indicates that air pollution may be associated with coronavirus disease 2019 (COVID-19) severity. We aimed to test whether (1) long-term exposure to air pollution is associated with COVID-19-related hospital admission or mortality in the general population; (2) short-term exposure to air pollution is associated with COVID-19-related hospital admission following COVID-19 diagnosis; (3) there are vulnerable population subgroups; and (4) the influence of long-term air pollution exposure on COVID-19-related hospital admissions differed from that for other respiratory infections. METHODS: We constructed a cohort covering nearly the full population of Catalonia through registry linkage, with follow- up from January 1, 2015, to December 31, 2020. Exposures at residential addresses were estimated using newly developed spatiotemporal models of nitrogen dioxide (NO(2)(3)), particulate matter =2.5 µm in aerodynamic diameter (PM(2.5)), particulate matter =10 µm in aerodynamic diameter (PM(10)), and maximum 8-hr-average ozone (O(3)) at a spatial resolution of 250 m for the period 2018-2020. RESULTS: The general population cohort included 4,660,502 individuals; in 2020 there were 340,608 COVID-19 diagnoses, 47,174 COVID-19-related hospital admissions, and 10,001 COVID-19 deaths. Mean (standard deviation) annual exposures were 26.2 (10.3) µg/m(3) for NO(2), 13.8 (2.2) µg/m(3) for PM(2.5), and 91.6 (8.2) µg/m(3) for O(3). In Aim 1, an increase of 16.1 µg/m(3) NO(2) was associated with a 25% (95% confidence interval [CI]: 22%-29%) increase in hospitalizations and an 18% (10%-27%) increase in deaths. In Aim 2, cumulative air pollution exposure over the previous 7 days was positively associated with COVID-19-related hospital admission in the second pandemic wave (June 20 to December 31, 2020). Associations of exposure were driven by exposure on the day of the hospital admission (lag0). Associations between short-term exposure to air pollution and COVID-19-related hospital admission were similar in all population subgroups. In Aim 3, individuals with lower individual- and area-level socioeconomic status (SES) were identified as particularly vulnerable to the effects of long-term exposure to NO(2) and PM(2.5) on COVID-19-related hospital admission. In Aim 4, long-term exposure to air pollution was associated with hospital admission for influenza and pneumonia: (6%; 95% CI: 2-11 per 16.4-µg/m(3) NO(2) and 5%; 1-8 per 2.6-µg/m(3) PM(2.5)) as well as for all lower respiratory infections (LRIs) (18%; 14-22 per 16.4-µg/m(3) NO(2) and 14%; 11-17 per 2.6-µg/m(3) PM(2.5)) before the COVID-19 pandemic. Associations for COVID-19-related hospital admission were larger than those for influenza or pneumonia for NO(2), PM(2.5), and O(3) when adjusted for NO(2). CONCLUSIONS: Linkage across several registries allowed the construction of a large population-based cohort, tracking COVID-19 cases from primary care and testing data to hospital admissions, and death. Long- and short-term exposure to ambient air pollution were positively associated with severe COVID-19 events. The effects of long-term air pollution exposure on COVID-19 severity were greater among those with lower individual- and area-level SES.
N. BARCLAY, E. BURN, A. DELMESTRI, T. DUARTE-SALLES, A. GOLOZAR, W. MAN, E. TAN, I. TIETZOVA, D. PRIETO-ALHAMBRA and D. NEWBY Aten Primaria.2022 Aug; 54(9):102437.doi:10.1038/s41598-024-69006-1 PMID:39153995
Breast cancer is the most frequently diagnosed cancer in females globally. However, we know relatively little about trends in males. This study describes United Kingdom (UK) secular trends in breast cancer from 2000 to 2021 for both sexes. We describe a population-based cohort study using UK primary care Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases. There were 5,848,436 eligible females and 5,539,681 males aged 18+ years, with >= one year of prior data availability in the study period. We estimated crude breast cancer incidence rates (IR), prevalence and survival probability at one-, five- and 10-years after diagnosis using the Kaplan-Meier method. Analyses were further stratified by age. Crude IR of breast cancer from 2000 to 2021 was 194.4 per 100,000 person-years for females and 1.16 for males. Crude prevalence in 2021 was 2.1% for females and 0.009% for males. Both sexes have seen around a 2.5-fold increase in prevalence across time. Incidence increased with age for both sexes, peaking in females aged 60-69 years and males 90+ . There was a drop in incidence for females aged 70-79 years. From 2003-2019, incidence increased > twofold in younger females (aged 18-29: IR 2.12 in 2003 vs. 4.58 in 2018); decreased in females aged 50-69 years; and further declined from 2015 onwards in females aged 70-89 years. Survival probability for females after one-, five-, and ten-years after diagnosis was 95.1%, 80.2%, and 68.4%, and for males 92.9%, 69.0%, and 51.3%. Survival probability at one-year increased by 2.08% points, and survival at five years increased by 5.39% from 2000-2004 to 2015-2019 for females, particularly those aged 50-70 years. For males, there were no clear time-trends for short-term and long-term survival probability. Changes in incidence of breast cancer in females largely reflect the success of screening programmes, as rates rise and fall in synchronicity with ages of eligibility for such programmes. Overall survival from breast cancer for females has improved from 2000 to 2021, again reflecting the success of screening programmes, early diagnosis, and improvements in treatments. Male breast cancer patients have worse survival outcomes compared to females, highlighting the need to develop male-specific diagnosis and treatment strategies to improve long-term survival in line with females.
T. LÓPEZ-JIMÉNEZ, O. PLANA-RIPOLL, T. DUARTE-SALLES, M. RECALDE, M. BENNETT, F. XAVIER-COS and D. PUENTE Aten Primaria.2022 Aug; 54(9):102437.doi:10.1002/cam4.7400 PMID:39149842
BackgroundMetabolic syndrome (MS) has emerged as a significant global health concern. The relationship between MS and the risk of cancer doesn’t seem clear, whether examining by components or in combination. The objective of this study is to examine the relationship between MS, its components, and the overall risk of cancer, including the risk of 13 specific cancer types.MethodsWe included 3,918,781 individuals aged 40 years or older sourced from the SIDIAP database between 2008 and 2017. Cox models were employed with MS components and their combinations. A subsample was created using a matched cohort (by age and sex). Incidence curves were computed to determine the time elapsed between the date of having 1-5 MS components and cancer incidence, compared to matched participants with no MS components, which showed that individuals who had one MS component experienced a greater incidence of cancer over 5 and 10 years than individuals with no MS, and the incidence rose with an increase in the number of MS components.ResultsIndividuals exposed to MS components were diagnosed with cancer earlier than those who were not exposed to them. In the Cox model, HDL (HR 1.46, 95% CI: 1.41-1.52) and Glycemia (HR 1.40, 95% CI: 1.37-1.44) were the individual combinations with the highest risk of overall cancer. In combinations with two components, the highest HR was HDL+Glycemia (HR 1.52, 95% CI: 1.45-1.59) and Glycemia+HBP (HR 1.48, 95% CI: 1.45-1.50). In combinations with three components, the highest HR was HDL+Glycemia+HBP (HR 1.58, 95% CI: 1.55-1.62).ConclusionIn summary, having one or more MS components raises the risk of developing at least 11 cancer types and these risk differ according to type of component included. Some sex differences are also observed. Our findings suggest that implementing prevention measures aimed at specific MS components may lower the risk of various cancer types.
X. CHEN, T. RATHOD-MISTRY, G. FABIANO, A. MOAYYERI, J. WARDEN, C. REYES, J. BRASH, K. VERHAMME, M. MOSSEVELD, S. SEAGER, R. PINEDO-VILLANUEVA and E. TAN Aten Primaria.2022 Aug; 54(9):102437.doi: PMID: